JP2014506244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506244A5 JP2014506244A5 JP2013544428A JP2013544428A JP2014506244A5 JP 2014506244 A5 JP2014506244 A5 JP 2014506244A5 JP 2013544428 A JP2013544428 A JP 2013544428A JP 2013544428 A JP2013544428 A JP 2013544428A JP 2014506244 A5 JP2014506244 A5 JP 2014506244A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- peptide
- subject
- concentration
- measuring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 102000003689 Complement Factor I Human genes 0.000 claims description 13
- 108090000044 Complement Factor I Proteins 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000000090 biomarker Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000004797 therapeutic response Effects 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 7
- 238000012360 testing method Methods 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010003805 Autism Diseases 0.000 description 10
- 208000020706 Autistic disease Diseases 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 8
- 229940123275 Complement factor I inhibitor Drugs 0.000 description 6
- 102100023795 Elafin Human genes 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108010015972 Elafin Proteins 0.000 description 4
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 4
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 4
- 229960005314 suramin Drugs 0.000 description 4
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 3
- 108050000761 Serpin Proteins 0.000 description 3
- 102000008847 Serpin Human genes 0.000 description 3
- SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 3
- IDIPWEYIBKUDNY-UHFFFAOYSA-N benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1 IDIPWEYIBKUDNY-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101001048718 Homo sapiens Elafin Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002366 time-of-flight method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42363610P | 2010-12-16 | 2010-12-16 | |
| US61/423,636 | 2010-12-16 | ||
| SE1051330 | 2010-12-16 | ||
| SE1051330-7 | 2010-12-16 | ||
| PCT/SE2011/051504 WO2012082056A1 (en) | 2010-12-16 | 2011-12-13 | Novel biomarker and uses thereof in diagnosis, treatment of autism |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2014506244A JP2014506244A (ja) | 2014-03-13 |
| JP2014506244A6 JP2014506244A6 (ja) | 2014-06-26 |
| JP2014506244A5 true JP2014506244A5 (https=) | 2015-01-29 |
| JP5960717B2 JP5960717B2 (ja) | 2016-08-02 |
Family
ID=45478452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013544428A Expired - Fee Related JP5960717B2 (ja) | 2010-12-16 | 2011-12-13 | 自閉症の診断、治療におけるバイオマーカーおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9347956B2 (https=) |
| EP (1) | EP2651972B1 (https=) |
| JP (1) | JP5960717B2 (https=) |
| CN (1) | CN103328501B (https=) |
| AU (1) | AU2011341776B2 (https=) |
| CA (1) | CA2821908C (https=) |
| ES (1) | ES2580136T3 (https=) |
| WO (1) | WO2012082056A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| WO2014203188A2 (en) * | 2013-06-19 | 2014-12-24 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel assay |
| WO2017027709A1 (en) | 2015-08-11 | 2017-02-16 | Cognoa, Inc. | Methods and apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CN105738631B (zh) * | 2016-02-22 | 2017-10-20 | 西安交通大学 | 一种孤独症血清多肽标志物serpina5‑a及其应用 |
| WO2018013811A1 (en) * | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
| EP3539033B1 (en) | 2016-11-14 | 2024-10-02 | Cognoa, Inc. | Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability |
| CN106596827B (zh) * | 2017-01-23 | 2019-06-07 | 上海知先生物科技有限公司 | Gal指标在自身免疫疾病治疗敏感性和疗效评估中的应用 |
| KR101796891B1 (ko) * | 2017-02-08 | 2017-11-13 | 재단법인대구경북과학기술원 | 뇌 시상하부 세포에서 tspo에 의한 대사체 변화 분석방법 |
| WO2018148262A1 (en) * | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
| US20220254461A1 (en) * | 2017-02-09 | 2022-08-11 | Cognoa, Inc. | Machine learning algorithms for data analysis and classification |
| CA3053245A1 (en) * | 2017-02-09 | 2018-08-16 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| CN118697876A (zh) * | 2017-02-09 | 2024-09-27 | 完美日光有限公司 | 用于自闭症谱系障碍药物治疗的方法 |
| GB201802116D0 (en) | 2018-02-09 | 2018-03-28 | Univ Warwick | Methods for diagnosing an autistic spectrum disorder |
| EP3773486B1 (en) * | 2018-04-04 | 2023-12-06 | Duke University | Umbilical cord tissue-derived mesenchymal stromal cells for use in the treatment of autism spectrum disorders |
| CN109293762A (zh) * | 2018-10-17 | 2019-02-01 | 湖北民族学院 | DRC3f抗原多肽，抗DRC3f的多克隆抗体及应用 |
| CN109813912B (zh) * | 2019-01-04 | 2021-12-28 | 深圳大学 | 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用 |
| KR102785528B1 (ko) | 2019-03-22 | 2025-03-21 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| AU2020343020A1 (en) | 2019-09-06 | 2022-03-31 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617308B2 (en) * | 2001-04-30 | 2003-09-09 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons |
| US6998243B2 (en) * | 2001-04-30 | 2006-02-14 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons |
| US20020160532A1 (en) * | 2001-04-30 | 2002-10-31 | George Jackowski | Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons |
| DE10158180A1 (de) | 2001-11-28 | 2003-09-11 | Biovision Ag | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
| SE0300586L (sv) * | 2003-03-04 | 2004-09-05 | Forskarpatent I Syd Ab | Diagnos av autism |
| CN102984493B (zh) * | 2012-11-21 | 2016-03-02 | 华为终端有限公司 | 视频数据传输的方法、装置及通信设备 |
-
2011
- 2011-12-13 US US13/994,671 patent/US9347956B2/en not_active Expired - Fee Related
- 2011-12-13 EP EP11808394.8A patent/EP2651972B1/en not_active Not-in-force
- 2011-12-13 JP JP2013544428A patent/JP5960717B2/ja not_active Expired - Fee Related
- 2011-12-13 WO PCT/SE2011/051504 patent/WO2012082056A1/en not_active Ceased
- 2011-12-13 AU AU2011341776A patent/AU2011341776B2/en not_active Ceased
- 2011-12-13 CN CN201180060249.6A patent/CN103328501B/zh not_active Expired - Fee Related
- 2011-12-13 CA CA2821908A patent/CA2821908C/en not_active Expired - Fee Related
- 2011-12-13 ES ES11808394.8T patent/ES2580136T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506244A5 (https=) | ||
| JP5960717B2 (ja) | 自閉症の診断、治療におけるバイオマーカーおよびその使用 | |
| JP2014506244A6 (ja) | 自閉症の診断、治療におけるバイオマーカーおよびその使用 | |
| US20240280591A1 (en) | Blood-based assay for detecting tauopathy or amyloidogenic disease | |
| BRPI1007443B1 (pt) | método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo | |
| CN119744269A (zh) | 抗tau mtbr抗体和检测tau的切割片段的方法及其用途 | |
| JP5713887B2 (ja) | 筋変性疾患の検出方法、及び治療効果判定方法 | |
| KR20160006432A (ko) | 경도인지장애 진단용 바이오마커 | |
| AU2023229388A1 (en) | Novel soluble urokinase plasminogen activator receptor (supar) binding molecules and uses thereof | |
| JP5267452B2 (ja) | 精神障害および／または腸のディスバイオシスのインビトロまたはエクスビボ診断方法 | |
| US20110263450A1 (en) | Alzheimer's disease biomarkers | |
| US20240218053A1 (en) | Engineering biologics to hpv oncoproteins | |
| US20130266976A1 (en) | Biomarkers associated with nephropathy | |
| JP2021522478A (ja) | 選択された患者の心血管疾患を治療するための組成物および方法 | |
| WO2008031190A1 (en) | Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases | |
| EP3290923A1 (en) | Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment | |
| JP6290398B2 (ja) | 多発性硬化症（ｍｓ）を監視する方法および予測キット | |
| EP2728358B1 (en) | Haptoglobin alpha-r as marker for diagnosing lung cancer | |
| JP6755649B2 (ja) | 虚血性疾患の診断マーカー | |
| JP2011232172A (ja) | βアミロイドに関連する病的状態の診断補助方法 | |
| WO2026033422A1 (en) | Methods to evaluate early-stage pre-tangle tau aggregates and treatment of alzheimer's disease | |
| WO2024235879A1 (en) | A NASAL FLUID SAMPLE COMPRISING Aβ, PTAU AND/OR TTAU | |
| WO2023220276A1 (en) | METHODS TO DETECT Aβ PROTEOFORMS AND USE THEREOF | |
| Galasko | Biological markers |